The Effectiveness of Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy: A Randomized, Controlled Clinical Trial


Aims/Introduction: Effectiveness of Diamel? on the biochemical variables: fasting blood glucose, postprandial glucose, cholesterol, triglycerides, and glycosylated haemoglobin [HbA1c] in type-2 diabetic patients receiving insulin terapy. Diamel is a natural product composed of trace elements: amino acids, vitamins, cranberry extract, and lettuce extract that have been activated by means of a magnetization process. Materials and methods: Randomized, doubleblind, comparator-controlled clinical trial. A central randomization centre used computer generated tables to allocate treatments. 116 patients suffering from type-2 diabetes mellitus treated with insulin at the Diabetes Care Centre in Pinar del Rio (Cuba), were recruited and randomly. The subjects were separated into two groups: Group A (n = 59), who were administered Diamel and Group B (n = 57) using placebo. The clinical and biochemical variables were assessed for 24 weeks. Results: Two subjects were excluded from the Diamel treatment group during the clinical trial. From the statistical point of view, a significant drop in the levels of the baseline glucose, postprandial glucose, glycated haemoglobin, and triglycerides was observed in the group taking Diamel (Group A). There was observed an increase in insulin requirements and in waist circumference in the subjects of Group B There was not reported any severe or serious adverse reactions during this clinical trial. Conclusion: Diamel (nutritional supplement) together with the administration of insulin in type-2 diabetic patients is useful to optimize the biochemical variables (baseline and postprandial glucose, Hb A1C, plus triglycerides), as well as to prevent the increase of insulin requirements at medium-term.

Share and Cite:

M. Elena de la Uz Herrera, A. Hernández Yero, R. González Iglesias, U. Reinoso Hernández, A. Novales Amado, M. del Carmen Herrera de la Uz and M. García Otero, "The Effectiveness of Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy: A Randomized, Controlled Clinical Trial," Open Journal of Endocrine and Metabolic Diseases, Vol. 2 No. 4, 2012, pp. 117-124. doi: 10.4236/ojemd.2012.24018.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] American Diabetes Association, “Diagnosis and Classification of Diabetes Mellitus,” Diabetes Care, Vol. 33, No. S1, 2010, pp. S62-S69. doi:10.2337/dc10-S062
[2] B. F. J. Ampudia, “Fallo Celular Beta y Progresión de la Diabetes Mellitus Tipo 2,” Endocrinology and Nutrition, Vol. 50, No. 7, 2003, pp. 274-279.
[3] R. González, E. Buchaca and M. Licea, “Fisiopatología y Progresión de las Personas con,” Revista Cubana de Endocrinología, Vol. 10, No. 1, 2011, pp. 11-17.
[4] UK Prospective Diabetes Study 16, “Overview of 6 Years Therapy of Type II Diabetes: A Progressive Disease. United Kingdom Prospective Diabetes Study Group,” Diabetes, Vol. 45, No. 11, 1996, pp. 1249-1258. doi:10.2337/diabetes.44.11.1249
[5] D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin, et al., “Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetes Care, Vol. 32, No. 1, 2009, pp. 193-203. doi:10.2337/dc08-9025
[6] R. Bastarrachea, J. Montero, V. Saavedra, R Cerda, A. Machado and A. Comuzzie, “Objetivos Moleculares Para Dise?ar Nuevos Fármacos Para el Tratamiento de la Diabetes Tipo 2 y la Obesidad,” Revista médica de Chile, Vol. 136, No. 1, 2008, pp. 107-117. doi:10.4067/S0034-98872008000100014
[7] J. L. Evans, I. P. Goldfine, B. A. Maddus and G. M. Grodsky, “Are Oxidative Stress-Activated Signalling Pathways Mediators of Insulin Resistance and Beta-Cell Dysfunction?” Diabetes, Vol. 52, No. 1, 2003, pp. 1-8. doi:10.2337/diabetes.52.1.1
[8] R. Robertson, J. Harmon, P. Oanh and V. Poitout, “Beta Cell Glucose Toxicity, Lipotoxicity and Chronic Oxidative Stress in Type 2 Diabetes,” Diabetes, Vol. 53, No. 1, 2004, pp. S119-S124. doi:10.2337/diabetes.53.2007.S119
[9] G. Orasanu and J. Plutzky, “The Pathologic Continuum of Diabetes Vascular Disease,” Journal of the American College of Cardiology, Vol. 53, No. 5, 2009, pp. S35-S42. doi:10.1016/j.jacc.2008.09.055
[10] Y. Yu and T. J. Lyons, “A Lethal Tread in Diabetes, Hyperglucemia, Dyslipemia, Oxidative Stress and Endothelial Dysfunction,” American Journal of Medical Science, Vol. 330, No. 5, 2005, pp. 227-232. doi:10.1097/00000441-200511000-00005
[11] J. M. Forbes, M. T. Coughlan and M. E. Cooper, “Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes,” Diabetes, Vol. 57, No. 6, 2008, pp. 1446-1454. doi:10.2337/db08-0057
[12] W. Jia, W. Gao and L. Tang, “Antidiabetic Herbal Drugs Offi cially Approved in China,” Phytotherapy Research, Vol. 17, No. 10, 2003, pp. 1127-1134. doi:10.1002/ptr.1398
[13] B. Ludvik, B. Neuffer and G. Pacini, “Efficacy of Ipomea Batatas (Caiapo) Ondiabetes Control in Type 2 Diabetes Subjects Treated with Diet,” Diabetes Care, Vol. 27, No. 2, 2004, pp. 436-440. doi:10.2337/diacare.27.2.436
[14] E. A. Sotoniemi, E. Haapakoski and A. Rautio, “Ginseng Therapy in Non-Insulindependent Diabetic Patients. Effect on Psychophysical Performance, Glucose Homeostasis, Serum Lipids, Serum Aminoterminal-Propeptide Concentration and Body Weight,” Diabetes Care, Vol. 18, No. 10, 1995, pp. 1373-1375.
[15] D. Cheta and F. Trifan, “Diamel Associated with Insulin or ADO or as a Pharmacological Monotherapy,” 2010.
[16] P. E. Milbury, B. Graf and J. M. C. Celentano, “Bilberry (Vaccinium myrtillus) Anthocyanins Modulate Heme Oxygenase-1 and Glutathione S-Transferasepi Expression in ARPE-19 Cells,” Investigative Ophthalmology and Visual Science, Vol. 48, No. 5, 2007, pp. 2343-2349. doi:10.1167/iovs.06-0452
[17] C. Olvera, G. Leo and H. Hernández, “Páncreas y Células Beta: Mecanismos de Diferenciación, Morfogénesis y Especificación Celular Endocrina. Regeneración?” Boletín Médico del Hospital Infantil de México, Vol. 65, No. 4, 2008, pp. 306-324.
[18] Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, “Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic Nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study,” The Journal of American Medical Association, Vol. 290, No. 16, 2003, pp. 2159-2167. doi:10.1001/jama.290.16.2159
[19] D. M. Nathan, P. A. Cleary, J. Y. Backlund, S. M. Genuth, J. M. Lachin, T. J. Orchard, et al., “Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes,” New England Journal of Medicine, Vol. 353, No. 25, 2005, pp. 2643-2653. doi:10.1056/NEJMoa052187
[20] S. Colagiuri, C. A. Cull and R. R. Holman, “Are Lower Fasting Plasma Glucose Levels at Diagnosis of Type 2 Diabetes Associated with Improved Outcomes? U.K. Prospective Diabetes Study 61,” Diabetes Care, Vol. 25, No. 8, 2002, pp. 1410-1417. doi:10.2337/diacare.25.8.1410
[21] A. Ceriello, “La ‘Memoria Metabólica’ Inducida por la Hiperglucemia: El Nuevo Reto en la Prevención de la Enfermedad Cardiovascular en la Diabetes,” Revista Espa?ola de Cardiología, Vol. 8, No. SC, 2008, pp. 12-18.
[22] J. A. Arguedas, “Effectividad y Seguridad Comparativa de los Medicamentos Para la Diabetes Tipo 2: Una Actualización Incluyendo Nuevas Drogas y Combinaciones de dos Drogas. Actualización Médica Periódica,” 2011.
[23] W. L. Bennett, N. M. Maruthur and S. Singh, “Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations,” Annals of Internal Medicine, Vol. 154, No. 9, 2011, pp. 602-613.
[24] R. Cabrera, “Diamel Intervention Trial on Metabolic Syndrome. AcciMonitor,” 2010.
[25] A. Hernández Yero and D. Vargas “Utilidad de Diamel en Pacientes con Diabetes Mellitus Tipo 2 en Tratamiento Combinado con Glibenclamida,” Avances en Diabetología, Vol. 23, No. 1, 2007, pp. 284-290.
[26] S. S. Sheu, D. Nauduri and M. W. Anders, “Targeting Antioxidants to Mitochondria: A New Therapeutic Direction,” Biochimica et Biophysica Acta, Vol. 1762, No. 2, 2006, pp. 256-265. doi:10.1016/j.bbadis.2005.10.007
[27] A. Gómez, E. Hernández, M. González and E. Martínez, “Efecto de la Administración Oral de Zinc Sobre Sensibilidad a la Insulina y Niveles Séricos de Leptina y Andrógenos en Hombres con Obesidad,” Revista médica de Chile, Vol. 134, No. 3, 2006, pp. 279-284.
[28] F. M. Vaz and R. Wanders, “Carnitine Biosynthesis in Mammals,” 2002.
[29] E. Trifan and D. Cheta, “Study on Use of Diamel in the Treatment of Diabetes Mellitus,” Nutritie si Boli Metabolic, Vol. 1, No. 1, 2002, pp. 23-38.
[30] E. Shafrir and I. Raz, “Diabetes: Mellitus or Lipidus?” Diabetologia, Vol. 46, No. 3, 2003, pp. 433-440.
[31] R. A. DeFronzo, “Insulin Resistance, Lipotoxicity, Type 2 Diabetes and Atherosclerosis: The Missing Links. The Claude Bernard Lecture 2009,” Diabetologia, Vol. 53, No. 7, 2010, pp. 1270-1287. doi:10.1007/s00125-010-1684-1
[32] R. Hernando, “Etiología y Fisiopatología de la Diabetes Mellitus Tipo 2,” Revista México de Cardiology, Vol. 22, No. 1, 2011, 5 p.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.